Status:
COMPLETED
French Study In ICU Patients Treated With Tigecycline
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Bacterial Infections
Eligibility:
All Genders
18+ years
Brief Summary
This study will describe clinical outcome and safety data collected prospectively in subjects hospitalized in an intensive care unit (ICU) presenting with an infection for which treatment with tigecyc...
Detailed Description
Healthcare visit. Extension Rationale: In order to perform the necessary corrective actions required and to secure database consistency, we request an extension for posting of Basic Results due 26-M...
Eligibility Criteria
Inclusion
- Adult men and women (18 years).
- Subjects hospitalized in a medical or surgical intensive care unit (ICU) (on the day of enrolment in the study).
- Subjects treated with tigecycline (first, second or third line), said treatment freely chosen by the participating physician, prior to enrollment in the study.
Exclusion
- Subjects participating in another biomedical research study.
- Patient (or legal representative) who has not dated or signed informed consent document.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT00799591
Start Date
September 1 2008
End Date
May 1 2010
Last Update
December 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Paris, France, 75018